Hepatitis B virus RNAs co-opt ELAVL1 for stabilization and CRM1-dependent nuclear export
Yingcheng Zheng,Mengfei Wang,Jiatong Yin,Yurong Duan,Chuanjian Wu,Zaichao Xu,Yanan Bu,Jingjing Wang,Quan Chen,Guoguo Zhu,Kaitao Zhao,Lu Zhang,Rong Hua,Yanping Xu,Xiyu Hu,Xiaoming Cheng,Yuchen Xia
DOI: https://doi.org/10.1371/journal.ppat.1011999
IF: 7.464
2024-02-03
PLoS Pathogens
Abstract:Hepatitis B virus (HBV) chronically infects 296 million people worldwide, posing a major global health threat. Export of HBV RNAs from the nucleus to the cytoplasm is indispensable for viral protein translation and genome replication, however the mechanisms regulating this critical process remain largely elusive. Here, we identify a key host factor embryonic lethal, abnormal vision, Drosophila-like 1 (ELAVL1) that binds HBV RNAs and controls their nuclear export. Using an unbiased quantitative proteomics screen, we demonstrate direct binding of ELAVL1 to the HBV pregenomic RNA (pgRNA). ELAVL1 knockdown inhibits HBV RNAs posttranscriptional regulation and suppresses viral replication. Further mechanistic studies reveal ELAVL1 recruits the nuclear export receptor CRM1 through ANP32A and ANP32B to transport HBV RNAs to the cytoplasm via specific AU-rich elements, which can be targeted by a compound CMLD-2. Moreover, ELAVL1 protects HBV RNAs from DIS3+RRP6+ RNA exosome mediated nuclear RNA degradation. Notably, we find HBV core protein is dispensable for HBV RNA-CRM1 interaction and nuclear export. Our results unveil ELAVL1 as a crucial host factor that regulates HBV RNAs stability and trafficking. By orchestrating viral RNA nuclear export, ELAVL1 is indispensable for the HBV life cycle. Our study highlights a virus-host interaction that may be exploited as a new therapeutic target against chronic hepatitis B. Export of HBV RNAs from the nucleus to the cytoplasm is indispensable for viral protein translation and genome replication, however the mechanisms regulating this critical process remain largely elusive. We demonstrate that ELAVL1 recognizes HBV RNAs and recruits ANP32A and ANP32B to transport viral RNA from nucleus to cytoplasm via CRM1 pathway. CMLD-2, a drug with ELAVL1 binding potential, restricts HBV replication. Functional cure of chronic HBV infection would require combination of current therapies with additional novel agents. Export of HBV RNAs from the nucleus to the cytoplasm is indispensable for viral protein translation and genome replication. Our study provides a proof of concept illustrating that targeting ELAVL1 holds promise as a potential approach to suppress HBV.
microbiology,virology,parasitology